Global Renal Cell Carcinoma (RCC) Drugs Market to Reach $3.03 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on the Kidney Cancer Drugs market. The global market for Renal Cell Carcinoma (RCC) drugs is forecast to reach $3.03 billion by the year 2017. Key factors driving market growth include increase in treatment rate and diagnosed incidence, introduction of new emerging therapies, increased use of combination therapies, and introduction of more efficient and effective targeted therapies. Another potential growth driver for the RCC market would be the increased use of GSK’s recently approved multi-kinase inhibitor, Votrient.

Kidney Cancer Drugs: A Global Strategic Business Report

Global incidence of kidney cancer is on the rise. Despite being a smaller segment in the overall oncology market compared to other cancers, kidney cancer emerged as a key area of research and development, and attracted significant investments from various pharmaceutical and biotechnology majors. Though just five to six drugs are presently approved, there are many others in the pipeline, including targeted therapies that are expected to make kidney cancer market an active ground for competition in future. New and emerging therapies are counteracting the drawbacks associated with traditional treatment, such as Interleukin-2 and Interferon-alpha that are characterized by low response rate and poor tolerability. Targeted therapies, in particular, possess significant opportunities in capitalizing on these unmet medical needs.

Among the various types of kidney cancers, Renal Cell Carcinoma (RCC) is the predominant type of kidney cancer, accounting for about 90% of all kidney cancers. Key factors driving market growth include increase in treatment rate and diagnosed incidence, introduction of new emerging therapies, increased use of combination therapies, and introduction of more efficient and effective targeted therapies. Another potential growth driver for the RCC market would be the increased use of GSK’s recently 2009 FDA-approved multi-kinase inhibitor, Votrient. In addition, newer therapies, such as Wilex’s Rencarex (Girentuximab), which is presently in Phase III trials, and established targeted agents, such as Sutent, Avastin, and Nexavar are also being evaluated in adjuvant setting. Patients with localized as well as locally advanced cancer represent the target patient population for treatment with adjuvant therapy and targeted therapies.

With the highest number of kidney cancer cases, the United States and Europe leads the global market for RCC drugs, as stated by the new market research report on Kidney Cancer Drugs. Accounting for a major share of the market, the US constitutes the world’s largest market for RCC drugs. Growth is expected to mainly emanate from the Asia-Pacific market, which is forecast to register a CAGR of more than 14% during the analysis period. In terms of therapeutic class, Multikinase Inhibitors dominate the RCC drugs market globally. Of all the therapeutic options available for advanced RCC, Pfizer’s Sutent has transpired to show significant potential for the treatment of the disease, and demonstrated superior efficacy compared to the traditional standard treatment of Interleukin-2 and Interferon-alpha. Sutent is presently the standard of care for treatment of naïve patients with advanced RCC. Other RCC drugs include Bayer/Onyx’s Nexavar, Pfizer’s Torisel, Novartis’ Afinitor, Roche’s Avastin, and GlaxoSmithKline’s Votrient/Patorma.

Major players profiled in the report include AVEO Pharmaceuticals, AstraZeneca Plc., Bayer Schering Pharma AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck-Serono, Novartis AG, Pfizer Inc., WILEX AG, among others.

The research report titled “Kidney Cancer Drugs: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the kidney cancer drugs market, including the Renal Cell Carcinoma (RCC) market; the disease overview, symptoms, causes, and diagnosis; an overview of the presently available therapeutic classes, including multi-kinase inhibitors, mTOR, and others; the recent product approvals, the pipeline drugs, the key corporate initiatives, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for kidney cancer drugs market for the years 2008 through 2017 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key therapeutic classes analyzed include Multikinase Inhibitors, and other therapeutics classes.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Kidney_Cancer_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1300 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media